4.240GBp+0.95%Mkt Cap: 26.02M GBpP/E: —Last update: 2026-05-13
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeut…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
P/B43.80
P/S—
EV/EBITDA-6.86
EV/Revenue—
EPS (TTM)-0.01
EPS (Forward)-3.39
Cash Flow & Leverage
FCF Yield-9.72%
FCF Margin—
Operating CF-1.77M GBp
CapEx (TTM)1.65K GBp
Net Debt/EBITDA0.13
Net Debt-396.65K GBp
Technical
SMA 504.828 (-12.2%)
SMA 2007.038 (-39.8%)
Beta2.98
S&P 52W Chg24.23%
Avg Vol (30d)1.96M
Avg Vol (10d)1.71M
Technical Indicators
RSI (14)42.9
MACD-0.2575
MACD Signal-0.3111
MACD Hist.+0.0536
BB Upper4.899 GBp
BB Middle4.369 GBp
BB Lower3.839 GBp
BB Width24.26%
ATR (14)0.6939 GBp
Vol Ratio (20d)1.57x
52W Range
1.38616% of range19.40
52W High19.40 GBp
52W Low1.386 GBp
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE457.49%
ROA-254.19%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio1.21
Quick Ratio0.73
Book Value/Sh0.0010 GBp
Cash/Share0.0010 GBp
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBp
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.623.91M
Float484.15M
Insiders5.01%
Institutions19.39%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap26.02M GBp
Enterprise Value21.49M GBp
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-2.48M GBp
Revenue/Share—
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees6
Last Price4.240 GBp
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB0033711010